Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis.
about
Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease.Effect of live Salmonella Ty21a in dextran sulfate sodium-induced colitisCholera toxin B: one subunit with many pharmaceutical applications.Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent.Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges.Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.Therapeutic effects of triptolide via the inhibition of IL-1β expression in a mouse model of ulcerative colitis.Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function.A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner.Cholera toxin B subunit promotes the induction of regulatory T cells by preventing human dendritic cell maturation.The cholera toxin B subunit directly costimulates antigen-primed CD4+ T cells ex vivo.Interleukin 6 inhibition by triptolide prevents inflammation in a mouse model of ulcerative colitis.Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease.Potent Anti-Inflammatory Activity of Tetramethylpyrazine Is Mediated through Suppression of NF-k.The immunosuppressor st1959, a 3,5-diaryl-s-triazole derivative, inhibits T cell activation by reducing NFAT nuclear residency.Therapeutic Potential of Cholera Toxin B Subunit for the Treatment of Inflammatory Diseases of the Mucosa.The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes.Genetic fusion of human insulin B-chain to the B-subunit of cholera toxin enhances in vitro antigen presentation and induction of bystander suppression in vivo.
P2860
Q34233126-BCD4B15D-3694-413C-B2E0-EA8E84B3037AQ35161765-95A1BBE1-351C-4FE6-8E3F-F37022E219B0Q35232735-52B4351F-5607-424F-B833-27C5C90BB765Q35619878-EC324945-40BC-4743-8F08-73E68C85310BQ35684429-09AC8FF6-2609-4860-BBA4-18D90472A220Q36923514-0E07FB75-4D71-4AF6-9095-2C9255196055Q37204119-2F5DA5F3-99CD-4E4C-BFC2-13027FD8B214Q37273216-4A48EFA6-774A-4DB0-9D4E-5030487310B7Q39749749-36DBAC76-EF77-4BD3-9AF8-C045FAAF1859Q39971245-5079CE75-327E-4BFA-978E-3F23F72BB8DEQ40564857-9A31849E-93E8-42F1-B44A-ABF43528F8DAQ41672388-A315E8D8-EE3F-45E3-95AB-0F38873EA84EQ41998304-E6F244D5-BCA2-44A6-9021-3BB7166E6B17Q42354667-ED2D439A-1662-4C57-9E9C-7564CB6E7AD3Q44015757-6CB6EA65-4E1A-406A-97A9-B0F2BB10BCF5Q47105986-176278FD-06ED-4C13-A311-BB661D0B2665Q47904800-689CF04C-A56D-41F9-9F6B-4ADC1CC60900Q54544388-5BFA3397-6EF3-4CC3-A541-50407A42E272
P2860
Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Oral administration of recombi ...... enzene sulfonic acid) colitis.
@ast
Oral administration of recombi ...... enzene sulfonic acid) colitis.
@en
type
label
Oral administration of recombi ...... enzene sulfonic acid) colitis.
@ast
Oral administration of recombi ...... enzene sulfonic acid) colitis.
@en
prefLabel
Oral administration of recombi ...... enzene sulfonic acid) colitis.
@ast
Oral administration of recombi ...... enzene sulfonic acid) colitis.
@en
P2093
P1476
Oral administration of recombi ...... enzene sulfonic acid) colitis.
@en
P2093
P304
P356
10.4049/JIMMUNOL.166.5.3522
P407
P577
2001-03-01T00:00:00Z